Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Aphios Corporation, a green biotechnology company developing enhanced therapeutic products for health maintenance, disease prevention, cancer and CNS disorder treatment has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation to develop Camposomes.
Subscribe to our email newsletter
Camposomes are phospholipid nanoencapsulated camptothecins used to treat pancreatic and other cancers. The subcontract is in support of the National Cancer Institute (NCI) Alliance for Nanotechnology, and the aim is to evaluate the potential of Aphios’ enabling nanotechnologies to improve the bioavailability, solubility, pharmacokinetics, or therapeutic index of a range of drugs that would otherwise fail as anti-cancer agents.
Aphios has utilised its patented SuperFluids CFN technologies to develop nanosomal formulations of paclitaxel , camptothecin and other poorly water-soluble therapeutics. It is anticipated that further research will improve the efficacy, reduce the toxicity, and improve the solubility and stability of this topoisomerase I inhibitor and anticancer drug.